The study will evaluate repeat low doses of psilocybin for safety, tolerability, and efficacy in treating generalized anxiety disorder (GAD) on a take-home basis, including an open-label follow-on extension. TORONTO, Jan. 24, 2023 /PRNewswire/ – Diamond Therapeutics Inc. (“Diamond”), a drug development company focused on low-dose psychedelic-derived therapies for use in the treatment of mental…


Previous articlePanel: Three Psychedelics Companies that Raised in 2022
Next articleSmall Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25